These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 37557072)

  • 1. Designing persuasive health education for patients seeking unproven stem cell interventions.
    Kawam O; Zhu X; Eton DT; Martin-Lillie C; Finney Rutten LJ; Shapiro S; Tilburt JC; Master Z
    Stem Cell Reports; 2023 Aug; 18(8):1549-1554. PubMed ID: 37557072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Academic physician specialists' views toward the unproven stem cell intervention industry: areas of common ground and divergence.
    Smith C; Crowley A; Munsie M; DeMartino ES; Staff NP; Shapiro S; Master Z
    Cytotherapy; 2021 Apr; 23(4):348-356. PubMed ID: 33563545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The involvement of Canadian physicians in promoting and providing unproven and unapproved stem cell interventions.
    Ogbogu U; Du J; Koukio Y
    BMC Med Ethics; 2018 May; 19(1):32. PubMed ID: 29716594
    [TBL] [Abstract][Full Text] [Related]  

  • 4. US state laws on medical freedom and investigational stem cell procedures: a call to focus on state-based legislation.
    Matthews KRW; Lowe SJ; Master Z
    Cytotherapy; 2024 Apr; 26(4):404-409. PubMed ID: 38310500
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unproven stem cell interventions: A global public health problem requiring global deliberation.
    Master Z; Matthews KRW; Abou-El-Enein M
    Stem Cell Reports; 2021 Jun; 16(6):1435-1445. PubMed ID: 34107243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The two-bucket problem of unproven stem cell interventions.
    Master Z
    Regen Med; 2023 Jan; 18(1):19-21. PubMed ID: 36221994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventions.
    Horner C; Tenenbaum E; Sipp D; Master Z
    NPJ Regen Med; 2018; 3():5. PubMed ID: 29479481
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Direct to Consumer Stem Cell Market and the Role of Primary Care Providers in Correcting Misinformation.
    Arthurs JR; Martin Lillie CM; Master Z; Shapiro SA
    J Prim Care Community Health; 2022; 13():21501319221121460. PubMed ID: 36112830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action.
    Caulfield T; Murdoch B
    BMC Med Ethics; 2019 Aug; 20(1):51. PubMed ID: 31383026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Industry Responsibilities in Tackling Direct-to-Consumer Marketing of Unproven Stem Cell Treatments.
    Master Z; Fu W; Paciulli D; Sipp D
    Clin Pharmacol Ther; 2017 Aug; 102(2):177-179. PubMed ID: 28695633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unproven stem cell-based interventions & physicians' professional obligations; a qualitative study with medical regulatory authorities in Canada.
    Zarzeczny A; Clark M
    BMC Med Ethics; 2014 Oct; 15():75. PubMed ID: 25315976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The roles and responsibilities of physicians in patients' decisions about unproven stem cell therapies.
    Levine AD; Wolf LE
    J Law Med Ethics; 2012; 40(1):122-34. PubMed ID: 22458467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Navigating persuasive strategies in online health misinformation: An interview study with older adults on misinformation management.
    Peng W; Meng J; Issaka B
    PLoS One; 2024; 19(7):e0307771. PubMed ID: 39052635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From the margins to mainstream: How providers of autologous 'stem cell treatments' legitimise their practice in Australia.
    MacGregor C; Petersen A; Munsie M
    Health (London); 2021 Jan; 25(1):51-68. PubMed ID: 31081381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Academic Physician Specialists' Approaches to Counseling Patients Interested in Unproven Stem Cell and Regenerative Therapies-A Qualitative Analysis.
    Smith C; Crowley A; Munsie M; Behfar A; DeMartino ES; Staff NP; Shapiro SA; Master Z
    Mayo Clin Proc; 2021 Dec; 96(12):3086-3096. PubMed ID: 34454715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Need for Beneficence and Prudence in Clinical Innovation with Autologous Stem Cells.
    Lipworth W; Stewart C; Kerridge I
    Perspect Biol Med; 2018; 61(1):90-105. PubMed ID: 29805150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How do I: Evaluate the safety and legitimacy of unproven cellular therapies?
    Guleria I; de Los Angeles Muñiz M; Wilgo M; Bapat A; Cui W; Hsu YS; Jeyaraman M; Muthu S; Rodriguez F; Fesnak A; Celluzzi C; Sesok-Pizzini D; Reich-Slotky R; Spitzer T
    Transfusion; 2022 Mar; 62(3):518-532. PubMed ID: 35143051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenging misinformation and engaging patients: characterizing a regenerative medicine consult service.
    Smith C; Martin-Lillie C; Higano JD; Turner L; Phu S; Arthurs J; Nelson TJ; Shapiro S; Master Z
    Regen Med; 2020 Mar; 15(3):1427-1440. PubMed ID: 32319855
    [No Abstract]   [Full Text] [Related]  

  • 20. Evidence-Based Strategies in Using Persuasive Interventions to Optimize Antimicrobial Use in Healthcare: a Narrative Review.
    Neo JRJ; Niederdeppe J; Vielemeyer O; Lau B; Demetres M; Sadatsafavi H
    J Med Syst; 2020 Feb; 44(3):64. PubMed ID: 32040649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.